a Background The efficiency of transient elastography for the assessment of liver fibrosis has been evaluated mainly in patients with chronic hepatitis C and chronic hepatitis B, with few studies with nonviral chronic liver disease (CLD) such as autoimmune hepatitis, alcoholic liver disease and nonalcoholic steatohepatitis. In this study, we examined the value of transient elastography in a number of groups in comparison with the Fibrotest/Actitest (FT/AT), using the liver biopsy (LB) as the reference standard.
Background The efficiency of transient elastography for the assessment of liver fibrosis has been evaluated mainly in patients with chronic hepatitis C and chronic hepatitis B, with few studies with nonviral chronic liver disease (CLD) such as autoimmune hepatitis, alcoholic liver disease and nonalcoholic steatohepatitis. In this study, we examined the value of transient elastography in a number of groups in comparison with the Fibrotest/Actitest (FT/AT), using the liver biopsy (LB) as the reference standard.
Methods An unselected and consecutive group of 65 patients had an LB either as part of an initial diagnosis or of a follow-up assessment, and in addition had a transient elastography measurement [Fibroscan (FS)] and serum blood tests FT/AT performed before the LB. The group consisted of patients diagnosed with a variety of CLD: chronic hepatitis C (n = 27), chronic hepatitis B (n = 8), alcoholic liver disease (n = 14), autoimmune hepatitis (n = 13) and nonalcoholic steatohepatitis (n = 4).
Results FS optimal cutoff values were 9.70 kPa for F at least 2, 13.00 kPa for F at least 3, and 16.00 kPa for F = 4. The areas under the receiver operating characteristic
Introduction
The prognosis and clinical management of chronic liver diseases (CLD) are frequently influenced by the extent of liver fibrosis, as life-threatening complications, including hepatocellular carcinoma, mainly occur within the clinical context of severe fibrosis [1] [2] [3] [4] . Especially in the group of chronic hepatitis C patients, the assessment of fibrosis and inflammation is crucial in determining progression of the liver lesion, and the need for antiviral treatment [5] . Liver function tests can also be a poor guide, in alcoholic liver disease (ALD), particularly during the more chronic stages [6] . The gold standard procedure for the assessment of the degree of fibrosis and the severity of inflammation, is the liver biopsy (LB) although it is invasive, with a definite though small morbidity, is also often not acceptable to patients, leading to treatment delays and can be difficult to justify repeated examinations [7, 8] . Furthermore, the accuracy of LB for assessing fibrosis and inflammation has been questioned, as it analyses only one of 50 000 of the liver and up to 30% of results can be false negatives [9] . 
Materials and methods

Patients
Seventy-six consecutive patients with CLD who underwent a percutaneous LB, a TE (FS) and an FT/AT on the same day were included in this study. The study conformed to the 1975 Helsinki Declaration and was approved by our institutional review board. Written informed consent was obtained from all patients before the procedures. Seven patients had unsuitable biopsy specimens and five patients had an unreliable LSM: the final analysis comprised of 65 outpatients at the stage of initial diagnosis or at follow-up. They were divided into the following aetiological groups: chronic hepatitis C (CHC, n=27), chronic hepatitis B (CHB, n=7), ALD (n=14), autoimmune hepatitis (AIH, n=13) and nonalcoholic steatohepatitis (NASH, n=4).
The diagnosis of CHC and CHB was based on the presence of the serological markers of hepatitis C and hepatitis B, and that of ALD on the following criteria: alcohol intake of greater than 80 g per day for more than 10 years, and the absence of other aetiological factors, including hepatitis B or C infection. For the diagnosis of AIH, the revised descriptive criteria for the diagnosis of AIH reported by the International Autoimmune Hepatitis Group were used [18] . Diagnostic criteria for NASH included an LB showing steatosis in at least 10% of hepatocytes, in addition to elevated serum aminotransferase levels.
Liver stiffness measurement
Measurement of liver stiffness was performed using an FS, (Echosens, Paris, France). All measurements were performed on the right lobe of the liver, through intercoastal spaces with the patient lying in dorsal decubitus with the right arm in maximal abduction position. The tip of the transducer probe was placed on the skin, between the ribs at the level of the right lobe of the liver. A liver portion at least 6 cm thick and free of large vascular structures was located by the operator, assisted by a timemotion ultrasound image. The measurement depth ranged between 25 and 65 mm. Ten validated measurements, expressed in kilopascals (kPa), were performed on each patient. The success rate was validated as the number of validated measurements divided by the total number of measurements. The median value was considered representative of the elastic modulus of the liver and only examinations with 10 validated measurements and a success rate of at least 60% were considered reliable.
Serum surrogate fibrosis markers
Fasting blood samples were obtained for biochemical tests (FT/AT, Lab 21, Cambridge, UK) performed by a laboratory regularly using these tests and meeting quality control standards. FT/AT blood tests comprised of the following measurements: a2-macroglobulin, haptoglobin, g-glutamyl-transferase, total bilirubin, apolipoprotein A1 and alanine aminotransferase. The FT/AT indexes were determined using the algorithm of Biopredictive [19] by external personnel, not involved in the planning of the study or the analysis of the data, strictly blinded to the LB and FS results.
Liver histology and quantification of liver fibrosis
An LB examination was performed using the Tru-Cut technique with an 18G Quick-Core biopsy needle (Cook, Bloomington, Indiana, USA) under ultrasound guidance. LB specimens were fixed in formalin and embedded in paraffin. Sections of liver tissue were stained with haematoxylin and eosin or elastic Masson's trichrome staining. All specimens were analysed by two independent, experienced liver pathologists, blinded to the results of LSM, FT/AT and clinical data. Only samples with a length of more than 10 mm were considered adequate. Liver fibrosis was evaluated according to the METAVIR scoring system with some modifications [20] . Fibrosis (F) was staged on a four-point scale as follows: F0=no fibrosis, F1=portal fibrosis, periportal fibrosis, or perisinusoidal fibrosis without septa, F2=portal fibrosis and few septa, F3=numerous septa without cirrhosis, and F4=cirrhosis. Necroinflammatory activity (A) was also evaluated on a four-point scale (A0=none, A1=mild, A2=moderate, A3=severe). The length of each specimen (in millimetres) and the number of fragments were recorded.
Statistical analysis
Results for fibrosis stage and grade of necroinflammatory activity were analysed according to aetiology group and for overall series. The trend between LSM and FT/AT and ordinate fibrosis stages and necroinflammation grades was estimated by the Spearman's r coefficient. The diagnostic performance of LSM and FT/AT was assessed in terms of sensitivity, specificity, positive predictive value (PPV), negative predictive values (NPV) and area under receiver operating characteristic curves (AUROC). A patient was assessed as positive or negative according to whether the noninvasive marker value was greater than, less than or equal to a given cutoff value. Optimal cutoff values between fibrosis stages and necroinflammatory grade categories were determined at the maximum sum of sensitivity and specificity. The significance level was set 0.05 and all P values were two-tailed. Statistical analyses were performed with SPSS 16.0 software (Chicago, Illinois, USA).
Results
Patients
Data analysis was performed on the basis of 65 patients [CHC, n=27: CHB, n=7: ALD, n=14: AIH, n=13: nonalcoholic fatty liver disease (NAFLD), n=4]. The characteristics are provided in Table 1 . Model For End Stage Liver Disease scores ranged between 5 and 8 with a median of 6, and none of the patients had symptoms of decompensated CLD. The patients of the viral CLD group were assessed either at the stage of initial diagnosis or during follow-up. The ALD patients were referred for further assessment and for diagnosis of possible liver damage. The median body mass index of the CHC patients was 25.7 (range [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] , and that for the NAFLD patients was 26 (range 25-28).
Histological assessment
The mean length of the LB samples was 17 mm and the median number of fragments was one (range 1-2). The fibrosis stages of the biopsy specimens for the complete group of patients were as follows: F0, n=24; F1, n=20; F2, n=8; F3, n=3; F4, n=10. Those for the viral CLD patients were F0, n=8; F1, n=11; F2, n=8, F3, n=2; F4, n=5. In the nonviral CLD group the stages were as follows: F0, n=16; F1, n=9; F2, n=0; F3, n=1, F4, n=5. The necroinflammation grades for the complete group of patients were A0, n=28; A1, n=36; A2, n=1; A3, n=0. In the viral CLD group the grades were as follows: A0, n=9; A1, n=25; A2, n=0; A3, n=0. Those of the nonviral group were A0, n=19; A1, n=11; A2, n=1; A3, n=0 ( Table 1) .
Relationship of liver stiffness measurements with histological stage
The liver stiffness values ranged between 3.2 and 65.2 kPa (median, 7.2 kPa). Figure 1 shows box-plots of FS values for each fibrosis stage as assessed histologically. The corresponding AUROCs are shown in Table 2 . The optimal cutoff values assessed from the distribution of stiffness values according to fibrosis stage ( Fig. 1 ) were 9.7 kPa for F Z 2, 13 kPa for F Z 3 and 15.25 kPa for F=4 (Tables 3 and 4 ). In patients with stiffness values greater than 9.7 kPa, the likelihood of significant fibrosis (F Z 2) was 71% (PPV). The PPV for the presence of severe fibrosis (F Z 3) was 56% above 13 kPa, and 54% for cirrhosis (F=4) above 16 kPa. The NPV for F Z 2, F Z 3 and F=4 were 90, 92 and 94%, respectively. Examination of the correlations using Spearman's coefficient (r) suggest strongly that liver stiffness values, and necroinflammation, as assessed on liver biopsies, were positively correlated [Spearman's coefficient r; 0.67 (P=0.01), 0.45 (P=0.01), respectively] with the liver fibrosis stage. Comparison of liver stiffness with serum Fibrotest Figure 1 shows box-plots of FS and FT for each fibrosis stage, and Fig. 2 shows the ROC curves for significant fibrosis (F Z 2), as assessed by liver biopsies. As shown in Table 2 A comparison of TE with the FT for the diagnosis of significant fibrosis (F Z 2) was performed. ROC curve analysis was performed for predicting significant fibrosis (F Z 2) in the complete group of patients, viral CLD patients and nonviral CLD patients, respectively (Fig. 2) . The AUROCs of FS and FT were 0.87 and 0.80, respectively, for the complete group of patients (n=65). The highest AUROC was obtained by FS. In the subgroup of viral CLD patients (n=34), the AUROCs of FS and FT were 0.88 and 0.78, respectively. The highest AUROC was obtained by the FS. In the subgroup of nonviral CLD patients (n=31), the AUROCs of FS and FT were as follows: 0.81 and 0.70, respectively. The differences among the AUROCs of FS and FT were not significant in clinical assessment.
Relationship between the stage of activity and Actitest values
The AUROC for A Z 2 was 0.83 (95% CI, 0.72-0.93). The best cutoff for A Z 2 was 0.50: sensitivity 0.6, specificity 0.85, PPV 0.85, NPV 0.65. The activity score correlated significantly with the Actiscore (Spearman's coefficient r=0.54, P=0.01).
Relationship among the ALT values, transient elastography measurements and Fibrotest values
Of note is that 38.5% of our study population had normal ALT values. Using Spearman's coefficient, the ALT values were positively correlated with the FS measurements (r=0.397, P=0.01), the FT (r=0.344, P=0.01) and the AT values (r=0.832, P=0.01). Although all the correlations are statistically significant, the strongest positive correlation observed was that for the Actitest.
Discussion
In this study, the performance of FS, in the assessment of liver fibrosis, was compared with the serum marker FT, taking LB as the reference point for the stage of fibrosis and inflammation grade. Of the two noninvasive methods, both the FS and the FT had similar diagnostic performance both for significant fibrosis (F Z 2) and for severe fibrosis-cirrhosis (F3-F4), as judged by AUROCs. The AUROCs for prediction of severe fibrosis (F Z 3) in the complete group of patients were 0.84 with FS measurements and 0.81 with the FT measurements, and the curves for predicting cirrhosis were 0.85 for the FS measurements and 0.84 for the FT. The FS and the FT had a virtually identical performance for predicting severe fibrosis and cirrhosis (F3-F4). Early detection of the stage of fibrosis as well as the grade of inflammation is important in the context of the management of CLD, so that progression to more severe fibrosis and cirrhosis can be prevented by more appropriate treatment means. Therefore, we compared the ability of TE and the FT to predict significant fibrosis (F Z 2) in patients with viral CLD and nonviral CLD. The AUROCs predicting significant fibrosis in patients with viral CLD and nonviral CLD were 0.88 versus 0.78 for the FS measurements and the FT, respectively. Furthermore, we did not observe a significant trend regarding the median liver stiffness values in the viral CLD and the nonviral CLD group, as the optimal cutoff for the diagnosis of significant fibrosis (F Z 2) was 9.6 kPa for the viral CLD group and 10.7 kPa for the nonviral CLD group, although the contrary has been reported [14] .
Limitations of TE include the difficulty of assessing obese patients [21] , with currently available probes, and the frequent failure of readings in patients with more than minimal ascites [16] . It is also apparent in the results of this study that necroinflammatory activity influences LSM, as Spearman's correlation coefficient shows a statistically significant correlation between FS measurements and activity as assessed histologically by liver biopsies. In clinical practice, interference by necroinflammatory activity and overlap between adjacent stages of liver fibrosis represents considerable limitation in the diagnostic accuracy of TE [22] . Of note is the finding that the FS was not found to have a positive predictive accuracy in the assessment of fibrosis at the F3-F4 stages and was used related to the METAVIR stages in a nonlinear manner, because TE assesses the amount of fibrosis, whereas the METAVIR score takes into account structural changes [9] . In most disease categories, those liver cases with a prolonged follow-up period is often needed after the initial evaluation of liver fibrosis and inflammatory activity, and noninvasive tests are more likely to prove to be of greater value in the assessment of disease progression [23] . It is of interest that a recent study reported a 5-year prognostic value of the FT similar to that of the LB [24] , but there are no similar data for the TE.
Furthermore, TE would appear to have a better performance for predicting significant fibrosis (META-VIR F Z 2) than minimal or no fibrosis (METAVIR F0-F1) [25, 26] . That might explain the slightly higher cutoff values of the FS measurements in our study, compared with the ones suggested by a recent metaanalysis [23] , as 67.7% of our patient cohort was of stage F0-F1. The discriminatory ability of such continuous scores as opposed to categorical variables, that is, the stage scores, can lead to discordant results. The ideal method of comparison among noninvasive tests' scores and a quantitative assessment of liver fibrosis would be a histological digital analysis of collagen, which has only been performed by Cales et al. [27] . A recent meta-analysis showed that a significant reduction in the heterogeneity of the AUROC was found when differentiating between the underlying liver diseases [23] . It should also be stressed that the relevance of a given cutoff value defined in a given population, may not be applicable to another population with a different prevalence. We therefore recommend for clinical practice the use of ranges of values rather than a single cutoff value to predict severity of fibrosis [28, 29] .
The variety of noninvasive markers of liver fibrosis shows that no single measure has achieved sufficiently good diagnostic performance [25] . Encouraging results have been reported by Lalazar et al. [30] on the methacetin breath test, which assesses intrahepatic inflammation and fibrosis. It has been reported that 67% of liver biopsies performed in a group of hepatitis C virus patients with normal ALT and significant fibrosis could have been avoided. Of note is that there are few studies on serum markers of liver fibrosis that include a wide range of liver diseases, such as the Fibrometer study [27] and the European Liver Fibrosis Study [31] . In the latter study, although the nine surrogate marker algorithm that was used had a sensitivity of 90% in depicting significant fibrosis and cirrhosis, the results did not correlate with the imaging assessment. Among the blood tests, the FT/AT blood test has been extensively evaluated [19, 32, 33] , and is licensed in several European countries and the US. In practice, the FT is the most widely used serum surrogate for the assessment of liver fibrosis and inflammation in viral CLD [34] , and it has not been evaluated extensively in nonviral CLD. In this study, the diagnostic performance of the FT/AT, as AUROC values depict, was slightly lower than those the FS, but clinically insignificant, providing useful information for both fibrosis and necroinflammation, without being affected by central obesity. The cost though, higher than that of standard liver function tests, is still substantially lower than that of the LB and of the FS assessment. In this study, we report that necroinflammatory activity influences the Actitest values. In this study, Spearman's correlation coefficient shows a statistically significant correlation between the AT values and necroinflammatory activity on histological assessment.
A possible explanation for some of the observed discordance between the gold standard LB and the noninvasive markers of fibrosis and inflammation is the sampling error. When paired biopsy specimens are analysed blindly, a one-stage change in the fibrosis score, most likely reflecting sampling error or interpreter variability, is not infrequently reported [33, 35] . Nevertheless, in patients with chronic viral hepatitis, there is a clear correlation between liver stiffness and the degree of liver fibrosis [10, 12, 14] . There are also limitations to the use of METAVIR score in patients with alcoholic hepatitis and NASH, as it does not evaluate the specific steatohepatitis feature of pericellular 'chicken-wire' fibrosis [36] . However, the subgroup analysis showed that the diagnostic accuracy of METAVIR in patients with alcoholic hepatitis or NASH did not substantially differ from that of the overall group.
Relatively, few studies to date have compared the efficiency of TE in the assessment of liver fibrosis in cohorts of patients with viral and nonviral CLD [13, 14, 17, 37] . LB is often considered necessary in the initial diagnosis of CHC and CHB infection as well as in assessing the extent of liver fibrosis and necroinflammation, although noninvasive methods may suffice for follow-up and in monitoring effects of antiviral therapy. It is also of considerable value in establishing the diagnosis of ALD, although an initial screening by one or other noninvasive technique may have a place in those concerned on account of their drinking habit [38] . Histological changes are an important part of scoring in the diagnosis process of AIH; furthermore, the diagnosis of NASH/NAFLD is essentially based on histopathology [18, 39, 40] . It is also important to identify a subset of patients with NAFLD with more advanced fibrosis, who are at risk of progressing to decompensated cirrhosis and hepatocellular carcinoma [41] [42] [43] . In patients with nonsignificant fibrosis, it may be sufficient to observe only [44] . However, patients with severe fibrosis or cirrhosis made up 20% of our patient group, a figure similar to or even lower than those reported by other clinical studies assessing noninvasive markers of liver fibrosis [10, 45] .
In conclusion, the combination of the FT/AT provides reliable measurements as an alternative to LB, and is likely to find an increasing case in the serial evaluation of patients with CLD. In terms of assessment of fibrosis, the FT would appear to be good, at least in statistical comparison with the FS, although the development of new probes such as the one for obesity may extend the range of conditions for which the FS can be used.
